

# SUSPECT ADVERSE REACTION REPORT

## I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) <b>PRIVACY</b>	1a. COUNTRY <b>COSTA RICA</b>	2. DATE OF BIRTH			2a. AGE	3. SEX	3a. WEIGHT	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION
		Day	Month	Year				Day	Month	Year	
		<b>PRIVACY</b>			<b>Unk</b>	<b>Female</b>	<b>Unk</b>		<b>Unk</b>		

  

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)						
Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)	Product	Serious	Listed	Reporter Causality	Company Causality	
Fever [Pyrexia]	TAGRISSO	No	No	Related	Related	
Diarrhea [Diarrhoea]	TAGRISSO	No	Yes	Related	Related	
Itchy skin [Pruritus]	TAGRISSO	No	Yes	Related	Related	
Fatigue [Fatigue]	TAGRISSO	No	No	Not Applicable	Related	
My nails are rotting [Nail infection]	TAGRISSO	No	Yes	Related	Related	
I get skin sores [Skin ulcer]	TAGRISSO	No	No	Related	Related	
my nose sometimes bleeds [Epistaxis]	TAGRISSO	No	Yes	Related	Related	

(Continued on Additional Information Page)

☐ PATIENT DIED☐ INVOLVED OR PROLONGED INPATIENT HOSPITALISATION☐ INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY☐ LIFE THREATENING☐ CONGENITAL ANOMALY☐ OTHER

## II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1 ) TAGRISSO (OSIMERTINIB) Tablet		20. DID REACTION ABATE AFTER STOPPING DRUG?  <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
15. DAILY DOSE(S) #1 ) 80 milligram, qd	16. ROUTE(S) OF ADMINISTRATION #1 ) Oral use	
17. INDICATION(S) FOR USE #1 ) Lung cancer (Lung neoplasm malignant)		21. DID REACTION REAPPEAR AFTER REINTRODUCTION?  <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
18. THERAPY DATES(from/to) #1 ) 20-JAN-2025 / Ongoing	19. THERAPY DURATION #1 ) Unknown	

## III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) #1 ) Rivotril (Clonazepam) ; Unknown #2 ) Loperamide (Loperamide hydrochloride) ; Unknown		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)		
From/To Dates Unknown to Ongoing	Type of History / Notes Indication	Description Lung cancer (Lung neoplasm malignant)

## IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER AstraZeneca Serban Ghiorgiu 1 Medimmune Way Gaithersburg, Maryland 20878 UNITED STATES Phone: +1 301-398-0000		26. REMARKS World Wide #: CR-ASTRAZENECA-202502003224CR Study ID: DMS (Disfruto Mi Salud) Case References: CR-AstraZeneca-CH-00801654A
	24b. MFR CONTROL NO. <b>202502CAM003224CR</b>	25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.  NAME AND ADDRESS WITHHELD.  NAME AND ADDRESS WITHHELD.
24c. DATE RECEIVED BY MANUFACTURER <b>02-JUN-2025</b>	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:	
DATE OF THIS REPORT <b>05-JUN-2025</b>	25a. REPORT TYPE <input type="checkbox"/> INITIAL <input checked="" type="checkbox"/> FOLLOWUP: 1	

05-Jun-2025 07:59

**ADDITIONAL INFORMATION****7+13. DESCRIBE REACTION(S) continued**

Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)	Product	Serious	Listed	Reporter Causality	Company Causality
there are foods I cant tolerate [Food intolerance]	TAGRISSO	No	No	Related	Related
I vomit [Vomiting]	TAGRISSO	No	No	Related	Related

Case Description: A solicited report has been received from a consumer in Patient Support Program. The report concerns a female patient born in 1972.

No medical history was reported.

Concomitant medication included Rivotril and Loperamide.

The patient started treatment with Tagrisso (osimertinib) 80 milligram qd, Oral use, on 20-JAN-2025 for lung cancer.

On an unknown date, the patient experienced i vomit (preferred term: Vomiting), my nails are rotting (preferred term: Nail infection), there are foods i cant tolerate (preferred term: Food intolerance), my nose sometimes bleeds (preferred term: Epistaxis), i get skin sores (preferred term: Skin ulcer), fatigue (preferred term: Fatigue), itchy skin (preferred term: Pruritus), diarrhea (preferred term: Diarrhoea) and fever (preferred term: Pyrexia).

The dose of Tagrisso (osimertinib) was not changed.

At the time of reporting, the event fever was improving. At the time of reporting, the event diarrhea, fatigue, i get skin sores, i vomit, itchy skin, my nails are rotting, my nose sometimes bleeds and there are foods i cant tolerate was ongoing.

The events were considered non-serious.

The reporter did not assess causality for fatigue. The reporter considered that there was a reasonable possibility of a causal relationship between Tagrisso and the following event(s): diarrhea, fever, i get skin sores, i vomit, itchy skin, my nails are rotting, my nose sometimes bleeds and there are foods i cant tolerate.

The company physician considered that there was a reasonable possibility of a causal relationship between Tagrisso and the following event(s): diarrhea, fatigue, fever, i get skin sores, i vomit, itchy skin, my nails are rotting, my nose sometimes bleeds and there are foods i cant tolerate.

Summary of follow up information received by AstraZeneca/MedImmune from consumer via solicited sources on 02-Jun-2025: new events of My nails are rotting, I get skin sores, my nose sometimes bleeds, there are foods I cant tolerate and I vomit added, consumer reporter added, start date of tagrisso was updated to 20-Jan-2025 from Jan-2025, consent to contact with reporter was updated to no from yes, narrative was updated. Non-significant correction on 04-Jun-2025: verbatim of the events of fever, fatigue, itchy skin and diarrhea were updated, unknown indication of concomitant drugs removed.